Key result
MYBPC1 LKR-duplication variant increases myosin binding but impairs myosin-ATPase activity and crossbridge cycling.
Why the study?
Myotrem is an untreatable, early-onset, congenital myopathy associated with dominant variants in the M-domain of slow-skeletal Myosin Binding Protein-C, but the molecular basis and structure of this domain remained uncharacterized.
The LKR-duplication in sMyBP-C alters global domain dynamics and increases myosin binding while impairing ATPase activity, elucidating the molecular basis of Myotrem myopathy.
Answers are grounded in this paper and cite their sources.
May inform Myotrem myopathy therapies; hypothesis-generating from animal data, requiring human validation.
Myotrem is an untreatable, early-onset, congenital myopathy characterized by hypotonia, muscle weakness, skeletal deformities, dysmorphia, respiratory insufficiency, and myogenic tremor (V. Shashi et al., Hum Mutat , 2019 and J. Stavusis et al., Ann. Neurol. , 2019). It is associated with dominant variants in the pivotal M-domain of slow-skeletal Myosin Binding Protein-C (sMyBP-C) that modulates the dynamic binding to myosin and actin filaments and thereby crossbridge formation and kinetics. Herein, we report a nonmissense Myotrem variant, c.795_803dup p.(Leu266_Arg268dup), referred to as LKR-duplication. Our comprehensive studies, integrating clinical findings with biophysical, structural, and computational approaches, uncover the previously unreported structure and properties of the slow-skeletal M-domain, while elucidating the impact of the LKR-duplication. We show that the LKR-duplication stabilizes local helicity but alters global domain dynamics, leading to increased myosin binding, while impairing myosin-ATPase activity and crossbridge cycling. Critically, we pinpoint the specific amino acid residues facilitating the M-domain/myosin interaction and demonstrate that the LKR-duplicated residues not only directly contribute to myosin binding but also enhance the myosin interacting capability of neighboring and distant residues. Our multimodal approach sheds light on aspects of the pathobiology of the slow-skeletal M-domain—the Myotrem hotspot—by unveiling underlying pathogenic etiologies thereby paving the way for the development of targeted treatments.
No takes yet. Share an insight, caveat, or question.
Iyer et al. (2026) studied Myotrem myopathy. LKR-duplication variant (c.795_803dup p.(Leu266_Arg268dup)) was evaluated. The LKR-duplication variant in MYBPC1 alters global domain dynamics, increasing myosin binding while impairing myosin-ATPase activity and crossbridge cycling.
Synapse has enriched 10 related papers. Consider them for comparative context: